Biolife Science Overview

  • Founded
  • 2012
Founded
  • Status
  • Public

Biolife Science General Information

Description

Imugene Ltd specializes is a clinical-stage immuno-oncology company. Its product includes HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being Research, Development, and Commercialisation of oncolytic immunotherapies.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • Level 11, 66 Eagle Street
  • Brisbane, Queensland 4000
  • Australia
+61 0402 000 000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Biolife Science Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biolife Science‘s full profile, request access.

Request a free trial

Biolife Science Executive Team (1)

Name Title Board Seat Contact Info
Paul Hopper Chief Operating Officer & Director
To view Biolife Science’s complete executive team members history, request access »